Jason R Stubbs

Summary

Affiliation: University of Kansas Medical Center
Country: USA

Publications

  1. ncbi request reprint Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
    Clin J Am Soc Nephrol 9:1965-73. 2014
  2. pmc Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Bone Miner Res 27:38-46. 2012
  3. ncbi request reprint Is fibroblast growth factor 23 a harbinger of mortality in CKD?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, 3901 Rainbow Blvd, Mail Stop 3002, Kansas City, KS 66160, USA
    Pediatr Nephrol 27:697-703. 2012
  4. ncbi request reprint Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Jason R Stubbs
    Division of Nephrology and Hypertension and The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Semin Dial 24:298-306. 2011
  5. pmc Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD
    Jason R Stubbs
    3901 Rainbow Boulevard, MS 3002, Kansas City, KS 66160, USA
    J Am Soc Nephrol 21:353-61. 2010
  6. pmc Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease
    Shiqin Zhang
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Kidney Int 84:713-21. 2013
  7. ncbi request reprint Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Am Soc Nephrol 18:2116-24. 2007
  8. ncbi request reprint Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
    Shiguang Liu
    Department of Internal Medicine and the Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, Room 6020 WHE, MS 3018, Kansas City, KS 66160, USA
    J Am Soc Nephrol 17:1305-15. 2006
  9. pmc FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
    Chad D Touchberry
    Muscle Biology Group, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA
    Am J Physiol Endocrinol Metab 304:E863-73. 2013
  10. ncbi request reprint Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA
    Nephrol News Issues 23:33-4, 36-7. 2009

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas
    Clin J Am Soc Nephrol 9:1965-73. 2014
    ....
  2. pmc Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Bone Miner Res 27:38-46. 2012
    ..Elevations in FGF23 and PTH coincide with an increase in urinary phosphate excretion that likely prevents the early onset of hyperphosphatemia in the face of increased bone turnover and a progressive decline in functional renal mass...
  3. ncbi request reprint Is fibroblast growth factor 23 a harbinger of mortality in CKD?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, 3901 Rainbow Blvd, Mail Stop 3002, Kansas City, KS 66160, USA
    Pediatr Nephrol 27:697-703. 2012
    ..This review highlights our current understanding of the regulation and function of FGF23 and examines the existing literature linking FGF23 with adverse outcomes...
  4. ncbi request reprint Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism?
    Jason R Stubbs
    Division of Nephrology and Hypertension and The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Semin Dial 24:298-306. 2011
    ..We also examine the potential nonclassical effects of these therapies on the renin-angiotensin-aldosterone system, proteinuria, vascular calcification, fibroblast growth factor-23, inflammation, and overall survival...
  5. pmc Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD
    Jason R Stubbs
    3901 Rainbow Boulevard, MS 3002, Kansas City, KS 66160, USA
    J Am Soc Nephrol 21:353-61. 2010
    ..These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD...
  6. pmc Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease
    Shiqin Zhang
    The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas, USA
    Kidney Int 84:713-21. 2013
    ..Thus, dietary phosphate restriction reduces the fractional excretion of phosphorus independent of serum FGF23 levels in mice with CKD...
  7. ncbi request reprint Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice
    Jason R Stubbs
    The Kidney Institute, University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Am Soc Nephrol 18:2116-24. 2007
    ....
  8. ncbi request reprint Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D
    Shiguang Liu
    Department of Internal Medicine and the Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, Room 6020 WHE, MS 3018, Kansas City, KS 66160, USA
    J Am Soc Nephrol 17:1305-15. 2006
    ..The physiologic role of FGF23 may be to act as a counterregulatory phosphaturic hormone to maintain phosphate homeostasis in response to vitamin D...
  9. pmc FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
    Chad D Touchberry
    Muscle Biology Group, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA
    Am J Physiol Endocrinol Metab 304:E863-73. 2013
    ..In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca(2+) regulation and contractile function during chronic kidney disease...
  10. ncbi request reprint Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?
    Jason R Stubbs
    Division of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS, USA
    Nephrol News Issues 23:33-4, 36-7. 2009
    ....